Ojer Pharma — Series B · €2.3M

Pamplona-based dermatology specialist Laboratorios Ojer Pharma raised a €2.3M capital increase with Inveready, Clave Mayor, Easo Ventures and Dozen Investments taking part and no single lead named; €1.7M came from 19 existing shareholders. Funds go to commercialising approved products, regulatory approvals for licensed products and new drug-delivery technology, following a €1.2M Series A in January 2020.